Novo Nordisk A/S

Latest Report Overview

Novo Nordisk A/S $NVO reported full-year 2025 revenue showing continued expansion in its core obesity and diabetes franchises, although growth is tempered by intensified competition. The company achieved significant revenue contributions from Wegovy, which grew 36% to DKK 79 billion, and Ozempic, with global sales exceeding DKK 127 billion. Operating margins remained robust in the 40%+ range, though capital allocation is heavily weighted toward aggressive manufacturing expansion to address previous supply constraints. Business performance in 2025 was defined by the rapid scale-up of production facilities to meet high demand, alongside a major internal organizational transformation that involved reducing the global workforce by approximately 9,000 employees. The company also navigated legal challenges in the US, specifically regarding the 340B Drug Pricing Program, which concluded in late 2025 with a favorable HRSA decision, allowing for a USD 4.2 billion revenue recognition in early 2026. Market share in the US for GLP-1 products faced headwinds due to increased competition from Eli Lilly. Management's outlook emphasizes the transition to a simplified organizational structure and continued focus on R&D to maintain a pipeline of innovative products. Priorities for 2026 include the successful integration of Akero Therapeutics (acquired December 2025), pilot programs for Medicare Part D obesity coverage, and navigating the implementation of negotiated drug prices for 2027.

Key Takeaways for Novo Nordisk A/S

• Novo Nordisk completed a company-wide transformation in 2025 that resulted in the reduction of approximately 9,000 employees to streamline decision-making.
• The acquisition of Akero Therapeutics was finalized in December 2025 for USD 4.7 billion plus CVRs to bolster the pipeline in MASH and metabolic disease.
• Novo Nordisk resolved 340B Drug Pricing Program litigation following a favorable December 2025 HRSA decision, allowing for the reversal of $4.2 billion in previous revenue constraints in early 2026.
• Wegovy Pill, the oral obesity treatment, was successfully launched in the first quarter of 2026, marking a significant extension of the product portfolio.
• Maziar Mike Doustdar assumed the role of President and CEO in August 2025, leading the strategic pivot towards obesity growth and operational simplification.
• The US market for GLP-1 diabetes and obesity treatments has seen market share pressure, with the lead for total weekly prescriptions shifting to a competitor during 2025.

What Does Novo Nordisk A/S Do?

Novo Nordisk is a global pharmaceutical company focused primarily on the discovery, development, and marketing of products for the treatment of serious chronic diseases. Its business is organized into two distinct operating segments: Obesity and Diabetes Care and Rare Disease. The company is a global leader in the GLP-1 (glucagon-like peptide-1) class of medicines, which includes high-performing assets like Ozempic, Wegovy, and Rybelsus. Additionally, the company maintains a legacy portfolio of insulin and blood-clotting factors. The company operates on a massive scale, employing approximately 69,500 people globally as of the end of 2025, following a major workforce optimization. Its primary production facilities are located in Denmark, the United States, France, China, and Brazil, reflecting a global supply chain strategy designed to support demand in approximately 170 countries. The business model is differentiated by its deep specialization in protein chemistry and the manufacturing of biologicals, which creates higher barriers to entry compared to traditional small-molecule pharmaceuticals.

Growth Drivers for Novo Nordisk A/S

• Continued global uptake of the GLP-1 product Wegovy for obesity, which grew 36% in 2025.
• Launch and market penetration of the oral formulation Wegovy Pill (launched Q1 2026).
• Expansion of manufacturing capacity through DKK 20B+ investments in facilities (e.g., Kalundborg, Denmark) to meet supply-demand gaps.
• Expansion into comorbidities such as MASH (metabolic dysfunction-associated steatohepatitis) via the Akero Therapeutics acquisition.
• Geographic expansion into emerging markets and increased access in US Medicare channels.